A consistency approach to evaluation of bridging studies and multi-regional trials

Statistics in Medicine

Volumn 30, Issue 17, 2011, Pages 2171-2186

  Tsou, Hsiao Hui ^a   Chien, Tuan Ying ^b   Liu, Jen Pei ^a,c   Hsiao, Chin Fu ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Polyolefin Division   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Bayesian most plausible prediction; Bridging study; Multi regional study; Similarity

Indexed keywords

ARTICLE; BAYES THEOREM; INTERNAL CONSISTENCY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PROBABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS;

ANTIHYPERTENSIVE AGENTS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; MULTICENTER STUDIES AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 79960011508     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4251     Document Type: Article

References (12)

1. ICH, International Conference on Harmonisation. Tripartite Guidance E5 Ethnic Factors in the Acceptability of Foreign Data. The U.S. Federal Register 1998; 83:31790-31796.
2. Shih WJ. Clinical trials for drug registration in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. Controlled Clinical Trials 2001; 22:357-366.
3. Chow SC, Shao J, Hu OYP. Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics 2002; 12:385-400. DOI: 10.1081/BIP-120014567.
4. Lan KK, Soo Y, Siu C, Wang M. The use of weighted Z-tests in medical research. Journal of Biopharmaceutical Statistics 2005; 15(4):625-639. DOI: 10.1081/BIP-200062284.
5. Hsiao CF, Hsu YY, Tsou HH, Liu JP. Use of prior information for Bayesian evaluation of bridging studies. Journal of Biopharmaceutical Statistics 2007; 17:109-121. DOI: 10.1080/10543400601001501.
6. Ministry of Health, Labour and Welfare of Japan. Basic Principles on Global Clinical Trials 2007. Available from: [22 October 2010].
7. ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q&A for the ICH E5 Guldeline on Ethnic Factors in the Acceptability of Foreign Data 2006. Available from: [22 October 2010].
8. Kawai N, Chuang-Stein C, Komiyama O, Ii Y. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 2008; 42:139-147.
9. Quan H, Zhao PL, Zhang J, Roessner M, Aizawa K. Sample size considerations for Japanese patients based on MHLW guidance. Pharmaceutical Statistics 2010; 9:100-112. DOI: 10.1002/pst.380.
10. Uesaka H. Sample size allocation to regions in a multiregional trial. Journal of Biopharmaceutical Statistics 2009; 19:580-595. DOI: 10.1080/10543400902963185.
11. Ko FS, Tsou HH, Liu JP, Hsiao CF. Sample size determination for a specific region in a multi-regional trial. Journal of Biopharmaceutical Statistics 2010; 20:870-885. DOI: 10.1080/10543401003618900.
12. Aitchison J, Dunsmore IR. Statistical Prediction Analysis. Cambridge University Press: Cambridge, 1975; 29-30.